Why Merck KGaA Is Paying a 130% Premium for This Gene-Silencing Tech

Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。